AMN107: Tightening the grip of imatinib

Cancer Cell

Volumn 7, Issue 2, 2005, Pages 117-119

  O'Hare, Thomas ^a   Walters, Denise K ^a   Deininger, Michael W N ^b   Druker, Brian J ^a,b  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB; ONO 12380; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

CANCER PATIENT; CANCER RECURRENCE; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SENSITIVITY; HUMAN; HYDROPHOBICITY; IC 50; LEUKEMIA REMISSION; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; TARGET CELL DESTRUCTION; WILD TYPE;

EID: 13844251983     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2005.01.020     Document Type: Short Survey

References (13)

1. M.W. Deininger, and B.J. Druker SRCircumventing imatinib resistance Cancer Cell 6 2004 108 110
2. M. Deininger, E. Buchdunger, and B.J. Druker The development of imatinib as a therapeutic agent for chronic myeloid leukemia Blood 2004 000 000 10.1182/blood-2004-08-3097
3. B.J. Druker, S. Tamura, E. Buchdunger, S. Ohno, G.M. Segal, S. Fanning, J. Zimmermann, and N.B. Lydon Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat. Med. 2 1996 561 566
4. B.J. Druker, M. Talpaz, D.J. Resta, B. Peng, E. Buchdunger, J.M. Ford, N.B. Lydon, H. Kantarjian, R. Capdeville, S. Ohno-Jones, and C.L. Sawyers Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N. Engl. J. Med. 344 2001 1031 1037
5. F. Giles, H. Kantarjian, B. Wassmann, J. Cortes, S. O'Brien, C. Tanaka, P. Rae, W. Mietlowski, A. Romano, and L. Alland A phase I/II study of AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, on a continuous daily dosing schedule in adult patients with imatinib-resistant advanced phase chronic myeloid leukemia (CML) or relapsed/refractory Philadelphia chromosome (Ph+) acute lymphocytic leukemia (ALL) Blood 104 2004 10a
6. K. Gumireddy, S.J. Baker, S.C. Cosenza, P. John, A.D. Kang, K.A. Robell, M.V. Reddy, and E.P. Reddy A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance Proc. Natl. Acad. Sci. USA 102 2005 1992 1997
7. A. Hochhaus, and P. La Rosée Imatinib therapy in chronic myelogenous leukemia: Strategies to avoid and overcome resistance Leukemia 18 2004 1321 1331
8. B. Nagar, W.G. Bornmann, P. Pellicena, T. Schindler, D.R. Veach, W.T. Miller, B. Clarkson, and J. Kuriyan Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571) Cancer Res. 62 2002 4236 4243
9. B. Peng, M. Hayes, D. Resta, A. Racine-Poon, B.J. Druker, M. Talpaz, C.L. Sawyers, M. Rosamilia, J. Ford, P. Lloyd, and R. Capdeville Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients J. Clin. Oncol. 22 2004 935 942
10. C.L. Sawyers, N.P. Shah, H.M. Kantarjian, N. Donato, J. Nicoll, S.A. Bai, F. Huang, E. Clark, A.P. DeCillis, and M. Talpaz Hematologic and cytogenetic responses in imatinib-resistant chronic phase chronic myeloid leukemia patients treated with the dual SRC/ABL kinase inhibitor BMS-354825: Results from a phase I dose escalation study Blood 104 2004 4a
11. T. Schindler, W. Bornmann, P. Pellicena, W.T. Miller, B. Clarkson, and J. Kuriyan Structural mechanism for STI-571 inhibition of abelson tyrosine kinase Science 289 2000 1938 1942
12. N.P. Shah, C. Tran, F.Y. Lee, P. Chen, D. Norris, and C.L. Sawyers Overriding imatinib resistance with a novel ABL kinase inhibitor Science 305 2004 399 401
13. E. Weisberg, P.W. Manley, W. Breitenstein, J. Brüggen, A. Ray, S.W. Cowan-Jacob, D. Fabbro, G. Fendrich, E. Hall-Meyers, and B.J. Huntly Characterization of AMN107, a selective inhibitor of wild-type and mutant Bcr-Abl this issue Cancer Cell 2005 000 000